Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2010

Cellectis Taps Helix Biocon to Promote Cell-Line Engineering Services in India

  • Cellectis bioresearch is teaming up with Indian firm Helix BioService & Consultants to promote its genome customization tools and services in India. The companies will pool their expertise to ensure maximum availability of Cellectis’ cellular Genome Positioning System (cGPS) product lines and to advance cell-line engineering services for bioproduction.

    “Cellectis bioresearch aims to make its products the gold standard in genome customization for the life science community throughout the world,” remarks Luc Selig, vp of sales and marketing at Cellectis bioresearch. “India, as a major player in bioproduction, is a key market for our cell-line engineering services. This new collaboration with Helix Biocon will bring our full line of products and services to the growing Indian science community.”

    Cellectis bioresearch was incorporated as a subsidiary of Cellectis in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization based on meganucleases. These molecular scissors enable targeted modifications to DNA with applications in the research, biomanufacturing, agrobiotechnology, and therapeutic sectors.

    To date Cellectis has reportedly formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers, and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »